Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medvin Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$12,652,997

439 payments

Through program year 2025, Medvin Clinical Research is reported as receiving $12,652,997 in research payments, across 439 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,100,156 19
2024 Research $1,302,860 44
2023 Research $845,601 142
2022 Research $1,230,172 145
2021 Research $616,937 53
2020 Research $506,898 11
2019 Research $50,374 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $9,361,000 30 payments
  2. Horizon Therapeutics plc $1,872,837 20 payments
  3. Novartis Pharmaceuticals Corporation $1,060,641 28 payments
  4. Ucb SA $125,714 5 payments
  5. Anika Therapeutics, Inc. $87,535 18 payments
  6. Kiniksa Pharmaceuticals, Ltd. $64,444 180 payments
  7. E.R. Squibb & Sons, L.L.C. $35,962 5 payments
  8. Ironwood Pharmaceuticals, Inc $12,579 2 payments
  9. Sun Pharmaceutical Industries Inc. $11,356 117 payments
  10. Boehringer Ingelheim International GmbH $9,677 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $7,371,834 4 payments
  2. P4 Uncontrolled Gout FORWARD II $1,090,462 1 payment
  3. Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $616,028 8 payments
  4. A Phase 1B, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects With Uncontrolled Gout Receiving Methotrexate $588,071 4 payments
  5. A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis $540,161 4 payments
  6. An Open-Label, Multi-Center Protocol for Patients Who Have Completed A Previous Novartis Sponsored Secukinumab Study and Are Judged By the Investigator to Benefit From Continued Secukinumab Treatment $492,070 3 payments
  7. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $339,710 2 payments
  8. A Two-Year, Phase III Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 MG S.C. Secukinumab Versus Placebo, in Combination With Soc Therapy, in Patients With Active Lupus Nephritis $332,832 5 payments
  9. A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $218,816 1 payment
  10. A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $105,182 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record